An innovative approach to the treatment of high-risk HPV patients using allokin-alpha

Abstract

Introduction. In the research literature, there have been recorded instances of imbalance of interleukins and tumour necrosis factors in the cervix tissues, endocervical mucus, suggestive of the potential feasibility of the use of immunomodulatory therapy.Purpose of the study. To assess the effectiveness of the use of the domestic drug allokin-alpha in the treatment of high-risk HPV infection (HPV) in patients of reproductive age, without elimination of the virus within more than 6–12 months and planning pregnancy.Materials and methods. The study included 60 patients of reproductive age with chronic HPV carriage – BP infection. They are represented in the study by two groups: 1st: 30 people in whose therapy allokin-alpha was not used (control group); and 30 patients without HPV BPV elimination in terms of more than 6–12 months, planning pregnancy and taking the domestic cytokiton-like immunomodulator allokin-alpha.Results. Spontaneous pregnancy occurred in 2/30 (6.7%) in the group without immunomodulator and in 9/30 patients in the group with allokin-alpha (30%) cases (c² = 5.45; p = 0.02; OR = 6.0 [1.17–30.72])Conclusion. The sustained virological response that we have achieved indicates the advisability of the use of allokin-alpha, a domestic immunomodulator of natural origin, in patients with high-risk chronic HPV infection and reproductive planning.